Cogent Biosciences, Inc. (NASDAQ: COGT) shares began Friday solidly in the green. The Waltham, Mass.-based biotechnology company focused on developing precision therapies for genetically defined diseases, today announced preclinical data from its novel, potential best-in-class JAK2 V617F mutant-selective inhibitor in a poster presentation at the 2026 European Hematology Association (EHA) Congress taking place in Stockholm June 11-14.
“We’re encouraged by the preclinical data from our next-generation JAK2 program being presented at EHA today,” said CEO Andrew Robbins.
“This highly selective, potent inhibitor of JAK2 V617F has the potential to address the underlying mutational driver of disease while mitigating off-target hematological effects. We are rapidly advancing this program and remain on track to submit our Investigational New Drug application in 2026.”
JAK2 V617F is the most prevalent molecular abnormality in BCR-ABL-negative myeloproliferative neoplasms (MPNs), occurring in approximately 95% of patients with polycythemia vera and 50% of patients with primary myelofibrosis or essential thrombocythemia. The poster highlights CGT1145, a potent inhibitor of the JAK2 V617F mutation with >100x selectivity over
JAK2 WT and the JAK1/3 isoforms, along with high oral bioavailability and low clearance across species.
CGT1145 has the potential to eradicate JAK2 V617F myeloproliferative neoplasm propagating cells and induce molecular remission with improved hematologic tolerability.
COGT shares leaped 69 cents, or 2.1%, to $33.31.
